GlaxoSmithKline (GSK)
NYSE:GSK
Want to see GSK full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.25Last Year’s EPS
1.24Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong operational and clinical positives: top‑line growth (sales +5%), specialty momentum (+14%), record Shingrix sales, robust HIV performance, positive Phase III readouts (bepirovirsen) and accelerated late‑stage pipeline activity including several acquisitions and pivotal trial starts. Challenges were acknowledged around established General Medicines declines, Trelegy headwinds, access and coding timing for new launches (notably Exdensur), diagnostic/testing gaps for hepatitis B adoption, R&D spending and some safety/operational considerations for ADCs. On balance, the positive commercial momentum, encouraging clinical data and clear execution on capital allocation and pipeline acceleration outweigh the headwinds, though several items are phasing‑sensitive and will be weighted to H2.Company Guidance
Quarterly Sales Growth
Total sales up 5% to more than GBP 7.6 billion in Q1 FY2026.
Specialty Medicines Growth
Specialty Medicines up 14%, a major driver of top-line growth.
Shingrix Performance
Shingrix delivered record quarterly sales of >GBP 1 billion, up 20% year‑on‑year; Europe growth +51% and U.S. growth +12%.
Profitability and EPS
Core operating profit grew 10% and EPS grew 9%, supported by favorable product mix and legal settlements.
Strong Cash Generation and Balance Sheet
Cash generation reported at GBP 1.4 billion; net debt at 1.4x EBITDA; free cash flow boosted by a $250 million special ViiV dividend and on‑track share buyback.
HIV Portfolio Momentum
HIV sales grew 10% in Q1; U.S. HIV sales +15%; Cabenuva grew 31%; Apretude grew 44%; 79% accelerated switches from competitor products in the U.S.
Nucala COPD Launch and Market Share
Nucala delivered double‑digit growth following U.S. COPD expansion; new patient starts +65% YoY and ~45% COPD market share in the U.S.; early China uptake ~50% of new COPD patients.
Oncology Successes (Jemperli, Mo‑Rez, Ris‑Rez)
Jemperli sales GBP 232 million, up 40% with RUBY 4‑year follow‑up showing 66% reduction in risk of death for dMMR MSI‑high endometrial cancer; Mo‑Rez Phase I highest‑dose confirmed ORR 62% (PROC) and 67% (advanced EC); Hansoh data for Ris‑Rez combo showed 47% ORR and median PFS 14 months.
Bepirovirsen Phase III Results and Regulatory Progress
Positive Phase III bepirovirsen data for functional cure in chronic hepatitis B; FDA breakthrough designation and PDUFA date set for 26 October; priority review accepted in China.
R&D and BD Acceleration
Multiple late‑stage program starts (7 Phase III in 2025; 10 more starting in 2026), acquisitions (35Pharma HS235 closed Apr 15; RAPT Therapeutics GBP 1.4bn upfront referenced), and plans for multiple pivotal trials (e.g., Ris‑Rez, Mo‑Rez, velzatinib).
GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $53.98 | $50.94 | -5.64% |
Feb 04, 2026 | $52.46 | $56.28 | +7.29% |
Oct 29, 2025 | $42.60 | $44.77 | +5.10% |
Jul 30, 2025 | $36.32 | $37.58 | +3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GlaxoSmithKline (GSK) report earnings?
GlaxoSmithKline (GSK) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is GlaxoSmithKline (GSK) earnings time?
GlaxoSmithKline (GSK) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GSK EPS forecast?
GSK EPS forecast for the fiscal quarter 2026 (Q2) is 1.25.
